Structure via PubChem · Public domain (PubChem)
abt-418
Sign in to saveABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not α3β4 receptors ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if anothe
In the Vinony graph
Vinony's link graph records 779 inbound references to abt-418, and connects out to barbiturates, agonist and nicotinic acetylcholine receptor.
It sits within the topics Chemical pages without DrugBank identifier, Drugboxes which contain changes to verified fields and Drugboxes which contain changes to watched fields.
Vinony links it to 4 Wikipedia language editions.
Chemical data
- Formula
- C9H14N2O
- Molecular weight
- 166.22 g/mol
- IUPAC name
- 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
- SMILES
- CC1=NOC(=C1)[C@@H]2CCCN2C
- InChIKey
- ILLGYRJAYAAAEW-QMMMGPOBSA-N
- XLogP
- 1.2
- Polar surface area
- 29.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Research
77 papers- ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity.Psychopharmacology · 1995
- Characterization of [3H]ABT-418: a novel cholinergic channel ligand.The Journal of pharmacology and experimental therapeutics · 1995
- Nicotinic acetylcholine receptors and epilepsy.Pharmacological research · 2023
- Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.Psychopharmacology · 1998
- The enhancement of contextual fear conditioning by ABT-418.Behavioural pharmacology · 2010
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 166.111
Show 5 more facts
- chemical formula
- C₉H₁₄N₂O
- canonical SMILES
- CC1=NOC(=C1)C2CCCN2C
- isomeric SMILES
- CC1=NOC(=C1)[C@@H]2CCCN2C
- subject has role
- nootropic
- Commons category
- ABT-418
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not α3β4 receptors ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.
== See also == Epiboxidine Anabaseine
Excerpted from Wikipedia’s “abt-418” article, available under the CC BY-SA 4.0 licence.